FDA has accepted for review a new supplemental Biologics License Application seeking approval for Keytruda (pembrolizumab) in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.
